Non-exclusive drug discount agreement for Naproxen (excluding syrup)
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Naproxen exklusive der Darreichung Sirup (ATC-Code nach WHO: M01AE02)
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No minimum purchase quantities; actual demand depends on prescription and pharmacy behavior. Revenue is entirely specul...
The buyer can terminate the Open-House model early if exclusive agreements are made, which typically happens 8-12 month...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Aug 31, 2028
Overview
Strong opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Aug 2028
- Supply of Naproxen (excluding syrup) pharmaceutical products
- Conclusion of non-exclusive discount agreements with AOK PLUS
Show full summary
This is a non-exclusive drug discount agreement (Rabattvereinbarung) under an Open-House model for the active substance Naproxen (excluding syrup), organized by AOK PLUS for the regions Saxony and Thuringia. The agreement is open to all interested pharmaceutical companies that meet the participation requirements. No minimum purchase quantities are guaranteed, and the contract ends at the latest on 31.08.2028. The procedure is not a classic public procurement but a voluntary publication for transparency.
Risks
No minimum purchase quantities; actual demand depends on prescription and pharmacy behavior. Revenue is entirely specul...
The buyer can terminate the Open-House model early if exclusive agreements are made, which typically happens 8-12 month...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical company as per § 4 Abs. 18 AMG for the offered products
- Company must have its seat in Germany, EU, or EEA
Eligibility
- Declaration of no exclusion grounds (§§ 123, 124 GWB) required
Requirements may be incomplete.
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive drug discount agreement for Naproxen (excluding syrup)
Conclusion of non-exclusive discount agreements for Naproxen (excluding syrup) under an Open-House model. The contract ends at the latest on 31.08.2028. No exclusivity, no minimum purchase quantities.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Naproxen exklusive der Darreichung Sirup (ATC-Code nach WHO: M01AE02)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 30 Jun 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 451272-2026
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No minimum purchase quantities; actual demand depends on prescription and pharmacy behavior. Revenue is entirely specul...
The buyer can terminate the Open-House model early if exclusive agreements are made, which typically happens 8-12 month...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications